These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15328825)

  • 1. Prevention and management of cardiotoxicity from antineoplastic therapy.
    Chanan-Khan A; Srinivasan S; Czuczman MS
    J Support Oncol; 2004; 2(3):251-6; discussion 259-61, 264-6. PubMed ID: 15328825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity of cytotoxic drugs.
    Schimmel KJ; Richel DJ; van den Brink RB; Guchelaar HJ
    Cancer Treat Rev; 2004 Apr; 30(2):181-91. PubMed ID: 15023436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
    Yeh ET; Tong AT; Lenihan DJ; Yusuf SW; Swafford J; Champion C; Durand JB; Gibbs H; Zafarmand AA; Ewer MS
    Circulation; 2004 Jun; 109(25):3122-31. PubMed ID: 15226229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
    Jones RL; Ewer MS
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1249-69. PubMed ID: 17020459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracycline cardiotoxicity in childhood.
    Ruggiero A; Ridola V; Puma N; Molinari F; Coccia P; De Rosa G; Riccardi R
    Pediatr Hematol Oncol; 2008 Jun; 25(4):261-81. PubMed ID: 18484471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Magné N; Chargari C
    Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Popat S; Smith IE
    Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer therapy induced cardiotoxicity: review of the literature.
    Geiger S; Lange V; Suhl P; Heinemann V; Stemmler HJ
    Anticancer Drugs; 2010 Jul; 21(6):578-90. PubMed ID: 20375725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy.
    Raschi E; Vasina V; Ursino MG; Boriani G; Martoni A; De Ponti F
    Pharmacol Ther; 2010 Feb; 125(2):196-218. PubMed ID: 19874849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug-induced cardiomyopathy].
    Takemoto Y; Yoshiyama M
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():440-4. PubMed ID: 18074578
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiotoxicity of antitumor drugs.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2008 May; 21(5):978-89. PubMed ID: 18376852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiac prevention: the oncologic point of view].
    Gligorov J; Debourdeau P; Arsovski O; Lotz JP
    Bull Cancer; 2004 Nov; 91 Suppl 3():192-200. PubMed ID: 15899627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced cardiovascular toxicity: beyond anthracyclines.
    Ai D; Banchs J; Owusu-Agyemang P; Cata JP
    Minerva Anestesiol; 2014 May; 80(5):586-94. PubMed ID: 24122036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
    Gianni L; Salvatorelli E; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
    Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice.
    Sukel MP; Breekveldt-Postma NS; Erkens JA; van der Linden PD; Beiderbeck AB; Coebergh JW; Herings RM
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):125-34. PubMed ID: 18058835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies.
    Adão R; de Keulenaer G; Leite-Moreira A; Brás-Silva C
    Rev Port Cardiol; 2013 May; 32(5):395-409. PubMed ID: 23623503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
    Fiúza M
    Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of systemic cancer treatment.
    Senkus E; Jassem J
    Cancer Treat Rev; 2011 Jun; 37(4):300-11. PubMed ID: 21126826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing treatment side effects in advanced breast cancer.
    Moore S
    Semin Oncol Nurs; 2007 Nov; 23(4 Suppl 2):S23-30. PubMed ID: 18054679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.